BR112016008973A2 - Adenovírus oncolítico munido de genes heterólogos - Google Patents
Adenovírus oncolítico munido de genes heterólogosInfo
- Publication number
- BR112016008973A2 BR112016008973A2 BR112016008973A BR112016008973A BR112016008973A2 BR 112016008973 A2 BR112016008973 A2 BR 112016008973A2 BR 112016008973 A BR112016008973 A BR 112016008973A BR 112016008973 A BR112016008973 A BR 112016008973A BR 112016008973 A2 BR112016008973 A2 BR 112016008973A2
- Authority
- BR
- Brazil
- Prior art keywords
- link
- heterologous genes
- sequence
- oncolytic adenovirus
- itr
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 3
- 230000000174 oncolytic effect Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
ADENOVÍRUS ONCOLÍTICO MUNIDO DE GENES HETERÓLOGOS. A presente revelação refere-se a um adenovírus de grupo B que compreende uma sequência de fórmula (I): 5 ITR-B1-BA-B2-BX-BB-BY-B3-3 ITR, em que: B1 é uma ligação ou compreende: E1A, E1B ou E1A-E1B; BA compreende -E2B-L1-L2-L3-E2A-L4; B2 é uma ligação ou compreende: E3; BX é uma ligação ou uma sequência de DNA que compreende: um sítio de restrição, um ou mais transgenes ou ambos; BB compreende L5; BY é uma ligação ou uma sequência de DNA que compreende: um sítio de restrição, um ou mais transgenes ou ambos; B3 é uma ligação ou compreende: E4; em que pelo menos um dentre BX ou BY não é uma ligação, composições farmacêuticas que compreendem o mesmo e uso dos vírus e composições em tratamento, particularmente no tratamento de câncer. A revelação também se estende a plasmídeos e processos empregados para preparar os ditos vírus.
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1318880.0A GB201318880D0 (en) | 2013-10-25 | 2013-10-25 | Adenovirus |
| GB201318885A GB201318885D0 (en) | 2013-10-25 | 2013-10-25 | Adenovirus |
| GB1318885.9 | 2013-10-25 | ||
| GB1318880.0 | 2013-10-25 | ||
| GBGB1322851.5A GB201322851D0 (en) | 2013-12-23 | 2013-12-23 | Method |
| GB1322851.5 | 2013-12-23 | ||
| GB201401159A GB201401159D0 (en) | 2014-01-23 | 2014-01-23 | Adenovirus |
| GB1401159.7 | 2014-01-23 | ||
| GB1406470.3 | 2014-04-10 | ||
| GB201406470A GB201406470D0 (en) | 2014-04-10 | 2014-04-10 | Virus |
| PCT/EP2014/072919 WO2015059303A1 (en) | 2013-10-25 | 2014-10-24 | Oncolytic adenoviruses armed with heterologous genes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016008973A2 true BR112016008973A2 (pt) | 2017-09-19 |
| BR112016008973B1 BR112016008973B1 (pt) | 2023-06-13 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500759B1 (en) | Oncolytic adenoviruses armed with heterologous genes | |
| BR112017005892A2 (pt) | variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma | |
| BR112018012179A2 (pt) | adenovírus de grupo b que codifica um anticorpo ou fragmento de complexo anti-tcr | |
| PH12017501942A1 (en) | Oncolytic adenovirus encoding a b7 protein | |
| BR112014032809A2 (pt) | melhora de autofagia ou aumento de longevidade pela administração de urolitinas ou precursores das mesmas | |
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| BR112018001995A2 (pt) | moléculas de ácido nucleico artificial | |
| EP4043021A3 (en) | Oncolytic tumor viruses and methods of use | |
| BR112012030711A2 (pt) | derivado de purinona | |
| BR112014019049A2 (pt) | adenovirus imunogênico | |
| BR112015008480A2 (pt) | compostos de benzeno substituído | |
| BR112017002053A2 (pt) | composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto | |
| BR112013028365A2 (pt) | "composição líquida compreendendo adi, composto compreendendo adi ligada covalentemente através de grupo de ligação a polietilenoglicol e uso de adi no preparo de composição para tratamento de câncer". | |
| BR112015004747A2 (pt) | moléculas oligonucleotídicas de fita dupla para p53 e métodos de uso das mesmas | |
| PE20150163A1 (es) | Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav | |
| BR112012029904A2 (pt) | métodos de purificação de polipeptídeos | |
| BR112015008612A2 (pt) | métodos de tratamento utilizando adenovirus | |
| BR112014028991A2 (pt) | triazóis como inibidores de kv3 | |
| BR112014012358A2 (pt) | 2-oxo-1,3-dioxolano-4-carboxamidas, sua preparação e uso | |
| BR112012023660A2 (pt) | novos métodos para direcionar células-tronco cancerosas | |
| BR112015006424A2 (pt) | grãos fundidos de sub-óxidos de titânio e produtos cerâmicos comportando tais grãos | |
| BR112017018305A2 (pt) | desacetoxitubulisina h e análogos da mesma | |
| BR112015007879A2 (pt) | inibidores do vírus da hepatite c | |
| BR112016000874A2 (pt) | vírus de rna oncolítico geneticamente estável, método de fabricação e uso dos mesmos | |
| BR112014032363A2 (pt) | produto de proteína de soja com ph neutro ou quase neutro ("s701n2") |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/10/2014, OBSERVADAS AS CONDICOES LEGAIS |
|
| B25D | Requested change of name of applicant approved |
Owner name: AKAMIS BIO LIMITED (GB) |
|
| B25G | Requested change of headquarter approved |
Owner name: AKAMIS BIO LIMITED (GB) |